UOC
UBS O'Connor Portfolio holdings
AUM
$1.93B
1-Year Return
38.75%
This Quarter Return
+10.85%
1 Year Return
+38.75%
3 Year Return
+182.42%
5 Year Return
+480.25%
10 Year Return
+1,573.29%
AUM
$3.16B
AUM Growth
-$2.43B
(-44%)
Cap. Flow
-$2.83B
Cap. Flow
% of AUM
-89.49%
Top 10 Holdings %
Top 10 Hldgs %
61.23%
Holding
616
New
86
Increased
50
Reduced
239
Closed
136
Top Buys
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$579M |
| 2 |
SPLK
Splunk Inc
SPLK
|
$454M |
| 3 |
HES
Hess
HES
|
$334M |
| 4 |
SRC
SPIRIT REALTY CAPITAL, INC.
SRC
|
$120M |
| 5 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$73.1M |
Top Sells
Sector Composition
| 1 | Energy | 29.73% |
| 2 | Technology | 22.08% |
| 3 | Healthcare | 10.58% |
| 4 | Real Estate | 7.31% |
| 5 | Industrials | 4.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Abbott
ABT
$231B
| $635K | 0.02% |
5,769
-43,231
| -88% | -$4.76M |
|
302
Intuit
INTU
$188B
| $625K | 0.02% |
1,000
-500
| -33% | -$313K |
|
303
Wayfair
W
$11.6B
| $617K | 0.02% |
10,000
-4,000
| -29% | -$247K |
|
|
AIV
304
Aimco
AIV
$1.11B
| $604K | 0.02% |
+77,150
| New | +$604K |
|
305
Astria Therapeutics
ATXS
$424M
| $600K | 0.02% |
78,120
-45,880
| -37% | -$352K |
|
306
Rezolute
RZLT
$696M
| $597K | 0.02% |
601,259
+43,952
| +8% | +$43.6K |
|
307
Leap Therapeutics
LPTX
$11.7M
| $595K | 0.02% |
143,589
-75,845
| -35% | -$314K |
|
308
First Industrial Realty Trust
FR
$6.92B
| $588K | 0.02% |
11,166
-206,323
| -95% | -$10.9M |
|
|
OSI
309
DELISTED
Osiris Acquisition Corp.
OSI
| $578K | 0.02% |
55,585
-24,985
| -31% | -$260K |
|
310
BridgeBio Pharma
BBIO
$10.2B
| $578K | 0.02% |
14,318
-42,982
| -75% | -$1.74M |
|
311
NXP Semiconductors
NXPI
$57.2B
| $574K | 0.02% |
+2,500
| New | +$574K |
|
|
BHAC
312
DELISTED
Focus Impact BH3 Acquisition Company Class A Common Stock
BHAC
| $565K | 0.02% |
54,209
-24,366
| -31% | -$254K |
|
313
Keros Therapeutics
KROS
$633M
| $561K | 0.02% |
14,112
-46,229
| -77% | -$1.84M |
|
314
Cullinan Oncology
CGEM
$413M
| $554K | 0.02% |
54,352
-50,648
| -48% | -$516K |
|
315
Workday
WDAY
$61.7B
| $552K | 0.02% |
2,000
-14,000
| -88% | -$3.86M |
|
316
AGNC Investment
AGNC
$10.8B
| $548K | 0.02% |
55,841
+6,422
| +13% | +$63K |
|
317
Disc Medicine
IRON
$2.11B
| $539K | 0.02% |
9,338
-13,783
| -60% | -$796K |
|
318
Ventas
VTR
$30.9B
| $518K | 0.02% |
+10,400
| New | +$518K |
|
319
Unity
U
$18.5B
| $511K | 0.02% |
+12,500
| New | +$511K |
|
320
Editas Medicine
EDIT
$248M
| $507K | 0.02% |
50,000
-32,369
| -39% | -$328K |
|
321
Pharvaris
PHVS
$1.48B
| $505K | 0.02% |
+18,000
| New | +$505K |
|
322
Vaxcyte
PCVX
$4.29B
| $504K | 0.02% |
8,030
-1,970
| -20% | -$124K |
|
323
Veru
VERU
$49.4M
| $504K | 0.02% |
+70,000
| New | +$504K |
|
324
Verastem
VSTM
$663M
| $503K | 0.02% |
61,803
-94,101
| -60% | -$766K |
|
325
Praxis Precision Medicines
PRAX
$986M
| $496K | 0.02% |
22,278
-16,625
| -43% | -$370K |
|